English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1748]
News [2788]
Articles [109]
Editorials [3]
Conferences [96]
elearning [7]
Prognostic model of all-cause mortality at 30 days in patients with cancer and...
Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA
Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )
11 Sep 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
11 Jul 2022
The advances in the management of patients with Hodgkin lymphoma and non...
Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute...
The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )
9 Jul 2022
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly...
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
28 Jun 2022
Cancer patient symptom and physical function reporting by caregivers used as...
Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco...
Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes ( Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, USA )
21 Jun 2022
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022
CAR-T cell therapy targeting BCMA is highly effective for patients with...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
A bispecific antibody talquetamab shows promising efficacy in relapsed...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab shows complete molecular response for patients with...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration in combination with pomalidomide...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022
<12345...146>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2023 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top